Commentary

Video

Findings for Zidesamtinib in Advanced ROS1+ NSCLC and Other Solid Tumors

Author(s):

Benjamin Besse, MD,Gregory J. Riely, MD, PhD

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Neil Iyengar, MD, and Chandler Park, MD, FACP
Eytan M. Stein, MD
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Eytan M. Stein, MD
Related Content
OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Non–Small Cell Lung Cancer | Image Credit: © Katsyarina – stock.adobe.com
December 30th 2024

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Felipe Batalini, MD, of Mayo Clinic
December 26th 2024

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer

NSCLC | stock.adobe.com
December 24th 2024

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC